Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 8/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 8/20 | 0.42 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.40 |
| ▸ | CDK2 | P24941 | 6/20 | 0.40 |
| ▸ | GRM5 | P41594 | 2/20 | 0.40 |
| ▸ | CDK1 | P06493 | 2/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | CCND3 | P30281 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2728585 | 0.80 | TNKS2 (0.33) | HTR2CTNKS2 | |
| SCHEMBL2727630 | 0.78 | HTR2C (0.34) | HTR2CTNKS2 | |
| SCHEMBL2985558 | 0.77 | CDK5 (0.43) | CDK5CDK5R1CCNA2CDK2GRM5 | |
| SCHEMBL4039246 | 0.75 | CDK5 (0.42) | CDK5CDK5R1CCNA2CDK2GRM5 | |
| SCHEMBL2732310 | 0.74 | HTR2C (0.42) | CDK5CDK5R1CCNA2CDK2GRM5 | |
| SCHEMBL10254995 | 0.74 | CDK5 (0.42) | CDK5CDK5R1CCNA2CDK2GRM5 | |
| SCHEMBL10251571 | 0.73 | CDK5 (0.41) | CDK5CDK5R1CCNA2CDK2GRM5 | |
| SCHEMBL15341621 | 0.72 | HTR2C (0.44) | CDK5CDK5R1CCNA2CDK2GRM5 | |
| SCHEMBL10251673 | 0.72 | CDK5 (0.39) | CDK5CDK5R1CCNA2CDK2CDK1 | |
| SCHEMBL14732931 | 0.72 | CDK5 (0.38) | CDK5CDK5R1CCNA2CDK2GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130281467-A1 | NOVEL MICROBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2013-10-24 | — | — | US | disclosed |
| EP-2632913-A1 | NOVEL MICROBICIDES | Syngenta Participations AG (CH) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012056003-A1 | NOVEL MICROBICIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130281467-A1 | NOVEL MICROBICIDES | CBR1, MSR1, CBR3 | CDK5 2406/4885CDK5R1 1373/4885CCNA2 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.